These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8483355)

  • 1. [Clozapine treatment of patients with schizophrenia. Great improvements with regard to symptoms and social life].
    Jonsson D; Zethraeus N; Mansfield M; Wålinder J
    Lakartidningen; 1993 Apr; 90(16):1564-6. PubMed ID: 8483355
    [No Abstract]   [Full Text] [Related]  

  • 2. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
    Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
    Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
    Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
    Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
    Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
    Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpretation of analysis.
    Heller JG
    Can J Clin Pharmacol; 2002; 9(3):129, 153; author reply 153. PubMed ID: 12474874
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
    Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
    Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies.
    Revicki DA
    J Clin Psychiatry; 1999; 60 Suppl 1():7-11; discussion 28-30. PubMed ID: 10037164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [4 years using clozapine in community psychiatry].
    Fremont P; Bazin N; Pillot B; Lochu A; Colen Demelo P; Pastol I; Zanata G
    Encephale; 1996 Dec; 22 Spec No 6():24-7. PubMed ID: 9102315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine for refractory schizophrenia: the Illinois experience.
    Buckman RW; Malan RD
    J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of clozapine on aggression and substance abuse in schizophrenic patients.
    Volavka J
    J Clin Psychiatry; 1999; 60 Suppl 12():43-6. PubMed ID: 10372611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quality of life of schizophrenic patients and clozapine].
    Raoul Y; Manesse P; Delage M
    Encephale; 1997 Sep; 23 Spec No 4():12-6. PubMed ID: 9417398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine's cost-benefits.
    Hosp Community Psychiatry; 1991 Jan; 42(1):92-4. PubMed ID: 1902817
    [No Abstract]   [Full Text] [Related]  

  • 15. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics.
    Mäkikyrö T; Leinonen E; Koponen H; Järvelin MR; Hakko H; Saarnisaari O; Isohanni M
    J Psychiatr Res; 1998; 32(2):105-10. PubMed ID: 9694006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in schizophrenia: beyond symptom reduction.
    Meltzer HY
    J Clin Psychiatry; 1999; 60 Suppl 3():3-7; discussion 8. PubMed ID: 10073370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New vs. old antipsychotics: the Texas experience.
    Reid WH
    J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model.
    Wang PS; Ganz DA; Benner JS; Glynn RJ; Avorn J
    J Ment Health Policy Econ; 2004 Jun; 7(2):77-85. PubMed ID: 15208468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Presentation of obsessive-compulsive symptoms in a patient with schizophrenia treated with clozapine].
    Stengler-Wenzke K
    Psychiatr Prax; 1999 May; 26(3):145-6. PubMed ID: 10412713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial.
    Essock SM; Hargreaves WA; Covell NH; Goethe J
    Psychopharmacol Bull; 1996; 32(4):683-97. PubMed ID: 8993092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.